-
pH 7.35 to 7.45– Mathematical Reasoning of Treatment Principle Based on Yin Yang Wu Xing Theory in Traditional Chinese Medicine (II)
Issue:
Volume 4, Issue 3, September 2020
Pages:
37-53
Received:
13 January 2017
Accepted:
18 December 2017
Published:
13 July 2020
Abstract: pH is useful in understanding disease. By using mathematical reasoning based on Yin Yang Wu Xing Theory in Traditional Chinese Medicine (TCM), this paper demonstrates that for the human blood pH value, the normal range of theory is [7.34539, 7.45461] nearly to [7.35, 7.45], and the center is 7.4. The first or second transfer law of human diseases changes according to the different human blood pH value whether in the normal range or not respectively. The treatment principle: “Don’t have disease cure cure non-ill” (不治已病治未病) is abiding by the first or second transfer law of human diseases. Assume that the range of a human blood pH value is divided into four parts from small to large. Both second and third are for a healthy body. The treating works are the prevention or the treatment for a more serious relation disease which comes from the first transfer law; And both first and fourth are for an unhealthy body. The treating works are the prevention or the treatment for a more serious relation disease which comes from the second transfer law. Human disease treatment should protect and maintain the balance of two incompatibility relations: the loving relationship and the killing relationship. As an application, the generalized method of drug treatment of heart is given.
Abstract: pH is useful in understanding disease. By using mathematical reasoning based on Yin Yang Wu Xing Theory in Traditional Chinese Medicine (TCM), this paper demonstrates that for the human blood pH value, the normal range of theory is [7.34539, 7.45461] nearly to [7.35, 7.45], and the center is 7.4. The first or second transfer law of human diseases c...
Show More
-
Attenuating the Post-Stroke Epilepsy Using the Si-Miao-Yong-An Decoction for Treatment
Shisheng Jiang,
Mukut Sharma,
Yuming Han,
Hongmei Wang,
Feizhou He,
Shuangteng He
Issue:
Volume 4, Issue 3, September 2020
Pages:
54-60
Received:
7 July 2020
Accepted:
27 July 2020
Published:
20 August 2020
Abstract: Objective: To observe the clinical efficacy of Si-Miao-Yong-An decoction (SMYAD) in the treatment of post-stroke epilepsy. Methods: 112 patients with post-stroke epilepsy were randomly assigned to either the control or the treatment group (56 subjects in each group). Patients in the control group received oral levetiracetam (LEV) combined with other conventional Western medicine treatment (s), while the treatment group received SMYAD only. Outcome measures were the duration for seizure remission, remission rates at one year, changes in electroencephalogram (EEG), scores of National Institutes of Health Stroke Scale (NIHSS), and adverse events in the two groups. Results: The numbers of patients who completed treatment were 41 and 55 in the LEV group and SMYAD group, respectively (P<0.01). After 12 months of treatment, epilepsy was controlled in 35 patients in LEV group and 47 in SMYAD group (P=0.990). Seizure remission was achieved in 15.1 days in LEV group and 8.7 days in SMYAD group (P<0.01). Relapse of epilepsy was observed in 19 cases in the LEV group and 11 in SMYAD group (P<0.01). Abnormal EEG patterns persisted in 32 patients in LEV group and 29 patients in SMYAD group (P<0.01). The NIHSS score decreased from 12.2 to 9.4 in LEV group, and from 12.5 to 5.8 in SMYAD group (P<0.01). Adverse effects of treatment were observed in 28 cases in LEV group and 6 patients in SMYAD group (P<0.01). The most common adverse events reported were rash, fatigue, somnolence, headache, and dizziness in LEV group, and diarrhea in SMYAD group. Adverse effects caused withdrawal of 8 patients from LEV group but none from SMYAD group (P<0.01). Conclusion: SMYAD is an effective and well tolerated remedy for post-stroke epilepsy. Further large scale randomized controlled trials are needed to establish the efficacy and tolerability.
Abstract: Objective: To observe the clinical efficacy of Si-Miao-Yong-An decoction (SMYAD) in the treatment of post-stroke epilepsy. Methods: 112 patients with post-stroke epilepsy were randomly assigned to either the control or the treatment group (56 subjects in each group). Patients in the control group received oral levetiracetam (LEV) combined with othe...
Show More
-
Clinical Study on Different Types of Insomnia Based on Conducting Yin from Yang, Conducting Yang from Yin Method with Spleen and Stomach as Center
Bian Wei,
Wang Huanqun,
Zou Weiwu,
Gan Ting
Issue:
Volume 4, Issue 3, September 2020
Pages:
61-66
Received:
17 August 2020
Accepted:
8 September 2020
Published:
19 September 2020
Abstract: [Objective] On the basis of observing Jinding Decoction (Glycyrrhiza 6g Poria 9g Pinellia 3g Guizhi 9g Peony 9g Long Bone 6g Oyster 9g), clinical research on different types of insomnia based on the pulse condition. [Method] Using the randomized parallel control method, 150 patients with insomnia who were treated in the Treatment Center and Brain Disease Department of our hospital from November 2019 to June 2020 were divided into treatment group, TCM control group, Western medicine control group, and TCM control group Adopting traditional Chinese medicine to collect through observation, hearing, and inquiring. According to the symptoms, tongue condition and pulse condition, the syndromes were differentiated one by one, followed by TCM classification and treatment. The western medicine control group was treated with alprazolam tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Zhunzi H32020215). Medicine treatment. 0.4 mg daily, orally 30 minutes before bedtime. Continuous treatment for 10 days is a course of treatment, each course is separated by 1 day, a total of 3 courses of treatment, observation of long-term efficacy observation before and after treatment were performed 1 day before the beginning of the treatment, the second day after the end of the treatment, and one month after stopping the treatment. Patients in the group were evaluated for clinical efficacy, PSQI score, and (SLC-90) score. [Results] Jinding Decoction had statistical significance in the treatment of insomnia of various syndrome types (P<0.05). [Conclusion] Spleen and stomach harmony is the basis for the orderly rise and fall of yin and yang qi, the hidden primordial spirit, and the foundation of sleep soundness. Jinding Decoction is based on the basic theory of traditional Chinese medicine.
Abstract: [Objective] On the basis of observing Jinding Decoction (Glycyrrhiza 6g Poria 9g Pinellia 3g Guizhi 9g Peony 9g Long Bone 6g Oyster 9g), clinical research on different types of insomnia based on the pulse condition. [Method] Using the randomized parallel control method, 150 patients with insomnia who were treated in the Treatment Center and Brain D...
Show More
-
Advances in Immunotherapy and Molecular Targeted Therapy for Castration Resistant Prostate Cancer
Issue:
Volume 4, Issue 3, September 2020
Pages:
67-70
Received:
31 August 2020
Accepted:
15 September 2020
Published:
23 September 2020
Abstract: Background: Prostate cancer is one of the most common cancer threats to men. The incidence rate and mortality rate are second only to lung cancer in Europe and America. At present, the 5-year survival rate of prostate cancer is only 29% when metastasis occurs. Prostate cancer seriously endangers the health of male patients. Early prostate cancer surgery and radiotherapy and chemotherapy effect is better, advanced endocrine therapy effect is better, because of drug resistance, eventually progress to castration resistant prostate cancer (CRPC). Although new drugs such as abiraterone acetate, enzalutamide, apalutamide and darutamide have brought new hope to patients with CRPC, when CRPC progresses to metastatic castration resistant prostate cancer (mCRPC), the effect of endocrine therapy is limited. Objective: Immunotherapy, immunosuppressive checkpoint inhibitors and molecular targeted therapy bring new hope to patients with CRPC. This article will review the new progress of immunotherapy and molecular targeted therapy. Methods: A number of clinical and experimental studies were reviewed to indicate the novel advancement in the progressive therapy of CRPC. Results: Immunotherapy, immunosuppressive checkpoint inhibitors and molecular targeted therapy can improve median survival time and have a decrease of PSA level. Conclusion: With the advancements in CRPC therapy made by the researchers, some novel potential methods will occupy more and more important position in the treatment of CRPC.
Abstract: Background: Prostate cancer is one of the most common cancer threats to men. The incidence rate and mortality rate are second only to lung cancer in Europe and America. At present, the 5-year survival rate of prostate cancer is only 29% when metastasis occurs. Prostate cancer seriously endangers the health of male patients. Early prostate cancer su...
Show More
